<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9607835</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20545</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Molecular psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">1359-4184</issn>
<issn pub-type="epub">1476-5578</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28461698</article-id>
<article-id pub-id-type="pmc">5668212</article-id>
<article-id pub-id-type="doi">10.1038/mp.2017.81</article-id>
<article-id pub-id-type="manuscript">NIHMS855614</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic Risk for Schizophrenia and Psychosis in Alzheimer Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>DeMichele-Sweet</surname>
<given-names>Mary Ann A.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weamer</surname>
<given-names>Elise A.</given-names>
</name>
<degrees>M.P.H.</degrees>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klei</surname>
<given-names>Lambertus</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vrana</surname>
<given-names>Dylan T.</given-names>
</name>
<xref ref-type="aff" rid="A7">g</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hollingshead</surname>
<given-names>Deborah J.</given-names>
</name>
<degrees>M.S.</degrees>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seltman</surname>
<given-names>Howard J.</given-names>
</name>
<degrees>M.D. Ph.D.</degrees>
<xref ref-type="aff" rid="A8">h</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sims</surname>
<given-names>Rebecca</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A11">k</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Foroud</surname>
<given-names>Tatiana</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A12">l</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hernandez</surname>
<given-names>Isabel</given-names>
</name>
<degrees>M.D., Ph.D.</degrees>
<xref ref-type="aff" rid="A9">i</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moreno-Grau</surname>
<given-names>Sonia</given-names>
</name>
<xref ref-type="aff" rid="A9">i</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tárraga</surname>
<given-names>Lluís</given-names>
</name>
<xref ref-type="aff" rid="A9">i</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boada</surname>
<given-names>Mercè</given-names>
</name>
<degrees>M.D., Ph.D.</degrees>
<xref ref-type="aff" rid="A9">i</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz</surname>
<given-names>Agustin</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A9">i</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Julie</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A11">k</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mayeux</surname>
<given-names>Richard</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lopez</surname>
<given-names>Oscar L.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sibille</surname>
<given-names>Etienne L.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A10">j</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kamboh</surname>
<given-names>M. Ilyas</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Devlin</surname>
<given-names>Bernie</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sweet</surname>
<given-names>Robert A.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A6">f</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>a</label>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA</aff>
<aff id="A2">
<label>b</label>Department of Neurology, University of Pittsburgh, Pittsburgh, PA</aff>
<aff id="A3">
<label>c</label>Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA</aff>
<aff id="A4">
<label>d</label>Genomics Research Core of the Health Sciences Core Research Facilities, University of Pittsburgh, Pittsburgh, PA</aff>
<aff id="A5">
<label>e</label>Departments of Neurology, Psychiatry and Epidemiology, Columbia University, New York, NY</aff>
<aff id="A6">
<label>f</label>VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC) VA Pittsburgh Healthcare System, Pittsburgh, PA</aff>
<aff id="A7">
<label>g</label>Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA</aff>
<aff id="A8">
<label>h</label>Department of Statistics, Carnegie Mellon University, Pittsburgh, PA</aff>
<aff id="A9">
<label>i</label>Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain</aff>
<aff id="A10">
<label>J</label>Departments of Psychiatry and of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada</aff>
<aff id="A11">
<label>k</label>Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK</aff>
<aff id="A12">
<label>l</label>Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA</aff>
<author-notes>
<corresp id="FN1">For questions and correspondence please contact: Robert A. Sweet, M.D., Mail: Biomedical Science Tower, Rm W-1645, 3811 O’Hara Street, Pittsburgh, PA 15213-2593. Express Mail: Biomedical Science Tower, Rm W-1645, Lothrop and Terrace Streets, Pittsburgh, PA 15213-2593. Phone: 412-624-0064, Fax: 412-624-9910, <email>sweetra@upmc.edu</email>, Web: <ext-link ext-link-type="uri" xlink:href="http://www.wpic.pitt.edu/research/sweetlab/">http://www.wpic.pitt.edu/research/sweetlab/</ext-link></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>23</volume>
<issue>4</issue>
<fpage>963</fpage>
<lpage>972</lpage>
<!--elocation-id from pubmed: 10.1038/mp.2017.81-->
<permissions>
<license>
<license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms" xlink:type="simple">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
</license>
</permissions>
<abstract>
<p id="P1">Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer Disease, affecting ~ 40% to 60% of individuals with AD (AD with psychosis, AD+P). In comparison to AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 61%, but the underlying genetic sources of this risk are not known. We evaluated a Discovery Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were genotyped using a custom genotyping array designed to evaluate SNPs with evidence of genetic association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia and Alzheimer disease. Results were replicated in an independent cohort of 2194 AD subjects with (N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal trafficking, autophagy, and calcium channel signaling. These findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. This provides an opportunity to leverage progress made in identifying the biologic effects of schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer Disease (AD+Psychosis, AD+P), affecting ~ 40% to 60% of individuals with AD. In comparison to AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Ropacki and Jeste<sup><xref ref-type="bibr" rid="R1">1</xref></sup> comprehensively reviewed the literature on psychosis in AD from 1990 to 2003, identifying 55 studies comprised of 9,749 subjects. More rapid cognitive decline was the most consistent correlate of AD+P compared to AD without psychosis (AD-P). More recent studies have continued to support the relationship between greater cognitive impairment, more rapid cognitive decline, and AD+P.<sup><xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R8">8</xref></sup> AD+P is further associated with additional psychiatric and behavioral disturbances, the most frequent and troublesome of which are agitation<sup><xref ref-type="bibr" rid="R9">9</xref></sup> and aggression<sup><xref ref-type="bibr" rid="R10">10</xref>;<xref ref-type="bibr" rid="R11">11</xref></sup>. AD+P leads to greater distress for family and caregivers<sup><xref ref-type="bibr" rid="R12">12</xref></sup>, greater functional impairment,<sup><xref ref-type="bibr" rid="R13">13</xref></sup> higher institutionalization rates,<sup><xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup> worse health<sup><xref ref-type="bibr" rid="R18">18</xref></sup> and increased mortality<sup><xref ref-type="bibr" rid="R19">19</xref></sup> compared to AD-P patients.</p>
<p id="P3">Treatment of psychosis in AD patients has been suboptimal due to the limited efficacy of available drugs and their high toxicity in this age group. First line treatments are atypical antipsychotics, which have efficacy similar to conventional antipsychotics for AD+P, with lower rates of motor side effects.<sup><xref ref-type="bibr" rid="R20">20</xref></sup> However, atypical and conventional antipsychotics have been associated with an increased risk of all-cause mortality after even short-term treatment.<sup><xref ref-type="bibr" rid="R20">20</xref>;<xref ref-type="bibr" rid="R21">21</xref></sup> Other treatments, such as selective serotonin reuptake inhibitors, may have some efficacy<sup><xref ref-type="bibr" rid="R22">22</xref>;<xref ref-type="bibr" rid="R23">23</xref></sup> and improved tolerability.<sup><xref ref-type="bibr" rid="R24">24</xref></sup> Nevertheless, none of these treatments was derived to prevent or reverse an identified biology of AD+P, and there is no current data to suggest that any of these treatments effectively mitigate against the greater cognitive and functional decline associated with AD+P. It is thus imperative to develop an approach to promote discovery regarding the biology of AD+P and identify opportunities to intervene to prevent its adverse trajectory.</p>
<p id="P4">We initially observed familial aggregation of AD+P,<sup><xref ref-type="bibr" rid="R25">25</xref></sup> since replicated in two independent cohorts.<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R26">26</xref></sup> These studies show a remarkable consistency in the estimated 3–4 fold increased odds of psychosis in a family member with AD, given the presence of psychosis in a proband with AD. Similarly, we used two of these cohorts to estimate the heritability of psychosis in AD as 61%.<sup><xref ref-type="bibr" rid="R27">27</xref>;<xref ref-type="bibr" rid="R28">28</xref></sup> Thus, AD+P is likely to be strongly influenced by genetic variation. In keeping with these observations, we recently reported the first Genome-Wide Association Study (GWAS) of AD+P, evaluating 1,299 cases with AD+P and 735 individuals characterized as AD-P. Although no single SNP demonstrated genome-wide significance, likely due to modest sample size, there was suggestive evidence for association with novel loci.</p>
<p id="P5">We further found a trend towards association with a group of 11 SNPs that had been identified in initial GWAS studies of schizophrenia and bipolar disorder.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> That latter finding also provided the biologically intriguing observation that the direction of 7/11 allelic effects on risk for AD+P were opposite that reported in the studies of psychiatric disorder subjects. Since the time of our prior report, genomic studies of schizophrenia risk have identified 128 SNPs in 108 loci that exceed genome-wide significance.<sup><xref ref-type="bibr" rid="R30">30</xref></sup></p>
<p id="P6">Recently, the use of polygenic risk scores has emerged as an important approach for summarizing genetic effects of a set of SNPs. A polygenic score is a simple, subject-specific summary of the additive effects of alleles on a trait. When computed to predict subjects’ risk for a disorder, it is called a polygenic risk score. The score can be obtained from a limited set of SNPs, such as those reaching genome wide significance in association studies, or a larger set based on some other threshold <sup><xref ref-type="bibr" rid="R31">31</xref><xref ref-type="bibr" rid="R32">32</xref><xref ref-type="bibr" rid="R33">33</xref></sup>, or the entire genome <sup><xref ref-type="bibr" rid="R34">34</xref>;<xref ref-type="bibr" rid="R35">35</xref></sup>. For example, when alleles at the 108 schizophrenia-associated loci were combined in a polygenic risk score they explained 3.4% of the liability to schizophrenia.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> For traits in which few or no individual SNPs reach genome wide significance, polygenic risk scores can provide initial evidence for true genetic association of the trait with the SNPs either included within the score or in close linkage disequilibrium <sup><xref ref-type="bibr" rid="R33">33</xref></sup>, providing critical evidence in support of larger scale studies needed to identify the individual affected loci.</p>
<p id="P7">Here we follow up on our prior research in an expanded Discovery Cohort of 2876 AD subjects with and without psychosis. All subjects were genotyped using a custom chip designed to evaluate SNPs with evidence of genetic association, most prominently with AD+P, although SNPs affecting or putatively affecting risk for schizophrenia and Alzheimer disease were also assessed. Results were replicated in an independent cohort of 2194 AD subjects with and without psychosis. We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. These findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. As efforts to identify the biologic effects of schizophrenia alleles progress, it may be possible to leverage these results to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<p id="P8">An overview of the study design and workflow is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<sec id="S3" sec-type="subjects">
<title>Subjects</title>
<p id="P9">This study analyzed samples obtained from subjects in two cohorts, an initial Discovery Cohort and an independent Replication Cohort (<xref ref-type="table" rid="T1">Table 1</xref>). All subjects were diagnosed with possible, probable,<sup><xref ref-type="bibr" rid="R36">36</xref></sup> or definite<sup><xref ref-type="bibr" rid="R37">37</xref></sup> AD. Importantly, subjects with a primary diagnosis of Dementia with Lewy bodies<sup><xref ref-type="bibr" rid="R38">38</xref></sup> were excluded. The above diagnoses resulted from diagnostic evaluations, cognitive testing, and in some cases neuropathologic assessment, conducted during subjects’ participation in the following programs as previously described: the University of Pittsburgh Alzheimer Disease Research Center (ADRC),<sup><xref ref-type="bibr" rid="R39">39</xref>;<xref ref-type="bibr" rid="R40">40</xref></sup> the Genetic and Environmental Risk in AD Consortium 1 (UK),<sup><xref ref-type="bibr" rid="R29">29</xref>;<xref ref-type="bibr" rid="R41">41</xref>;<xref ref-type="bibr" rid="R42">42</xref></sup> the National Institute on Aging’s Late Onset Alzheimer’s Disease Family Study (NIA-LOAD),<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R28">28</xref></sup> the National Institute of Mental Health Genetics Initiative AD Cohort (NIMH),<sup><xref ref-type="bibr" rid="R25">25</xref></sup> the Fundació ACE Barcelona Alzheimer Treatment and Research Center (ACE),<sup><xref ref-type="bibr" rid="R41">41</xref>;<xref ref-type="bibr" rid="R43">43</xref></sup>, the Cardiovascular Health Study (CHS),<sup><xref ref-type="bibr" rid="R3">3</xref>;<xref ref-type="bibr" rid="R41">41</xref></sup> and a consortium of National Institute on Aging Alzheimer Disease Centers (ADC).<sup><xref ref-type="bibr" rid="R44">44</xref></sup> Collection of clinical data and genetic samples were approved by each sites local Institutional Review Board or Medical Ethics Committee, as appropriate. Additional detail of the individual cohorts and assessment methodology is available in <xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref> and <xref ref-type="supplementary-material" rid="SD1">Tables S1–S13</xref>.</p>
</sec>
<sec id="S4">
<title>Characterization of Psychosis</title>
<p id="P10">Subjects were characterized for the presence or absence of delusions and hallucinations within the individual studies using the CERAD behavioral rating scale<sup><xref ref-type="bibr" rid="R45">45</xref></sup> (ADRC and NIA-LOAD), Neuropsychiatric Inventory Questionnaire (NPI-Q,<sup><xref ref-type="bibr" rid="R46">46</xref></sup> NIA-LOAD, ADC), NPI-Q Spanish Version<sup><xref ref-type="bibr" rid="R47">47</xref></sup> (ACE), NPI<sup><xref ref-type="bibr" rid="R48">48</xref></sup> (UK, CHS), and Brief Psychiatric Rating Scale<sup><xref ref-type="bibr" rid="R49">49</xref></sup> (NIMH). Each of these instruments has established reliability in AD,<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R50">50</xref></sup> and we have previously used all successfully in analyses of psychosis in AD subjects.<sup><xref ref-type="bibr" rid="R3">3</xref>;<xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R6">6</xref>;<xref ref-type="bibr" rid="R27">27</xref>;<xref ref-type="bibr" rid="R39">39</xref></sup> Details of the application of these assessments for each cohort are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref>. AD+P was defined by the presence of persistent hallucinations or delusions occurring during the course of the dementia, AD-P was defined by the absence of all symptoms at all assessments. Because psychotic symptoms typically emerge in the mild to moderate stages of AD<sup><xref ref-type="bibr" rid="R4">4</xref></sup> individuals without psychosis but who were still in the early stages of disease at their last assessment (Clinical Dementia Rating<sup><xref ref-type="bibr" rid="R51">51</xref></sup> score &lt;1, mini-mental state examination score<sup><xref ref-type="bibr" rid="R52">52</xref></sup> &gt;20) were considered to be at substantial risk of developing AD+P later in their course. Thus, these individuals were excluded from the analysis. We have previously used these approaches to characterizing and defining AD+P and AD-P to demonstrate familial aggregation,<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R25">25</xref></sup> heritability,<sup><xref ref-type="bibr" rid="R27">27</xref>;<xref ref-type="bibr" rid="R28">28</xref></sup> genetic linkage,<sup><xref ref-type="bibr" rid="R28">28</xref>;<xref ref-type="bibr" rid="R53">53</xref></sup> and suggestive genome-wide association<sup><xref ref-type="bibr" rid="R29">29</xref></sup> with the AD+P phenotype.</p>
</sec>
<sec id="S5">
<title>Genotyping</title>
<sec id="S6">
<title>DNA Preparation</title>
<p id="P11">Samples from outside sources were shipped on dry ice, stored, and processed by the Genomic Core Lab at the University of Pittsburgh. ACE samples were supplied as whole blood and genomic DNA was extracted using the Qiamp Blood Mini kit (Qiagen, Valencia, CA). All other centers provided genomic DNA (ADRC, NIA-LOAD, NIMH, UK, ADC) or whole genome amplified DNA (CHS).</p>
</sec>
<sec id="S7">
<title>Custom Chip for Discovery Cohort</title>
<p id="P12">The Genomic Core Lab quantitated all samples by Pico Green (Thermo Fisher, Pittsburgh, PA) and diluted the DNA to 23ng/ul and shipped the plates on dry ice to Affymetrix (Los Angeles, CA) for genotyping. Plates also contained randomized duplicates. Affymetrix confirmed all DNA concentrations by Pico Green assay prior to genotyping. Genotyping used a custom designed Axiom® chip (see SNP selection below), and was performed using the Affymetrix GeneTitan® system as described in the axiom user manual<sup><xref ref-type="bibr" rid="R54">54</xref></sup> with resultant genotype calls provided for QC and analysis.</p>
</sec>
<sec id="S8">
<title>iPlex Assay for Genotyping SCZ risk score SNPs and Replication Cohort Testing</title>
<sec id="S9">
<title>iPlex Chemistry</title>
<p id="P13">Assays were designed with Assay Designer 4.0 (Agena) and analysis performed using iPlex Gold Genotyping Reagent Set (Agena, San Diego, CA) according to manufacturer’s instructions. Target loci were amplified within the samples by multiplex PCR in 1X PCR buffer containing 3.5 mM MgCl<sub>2</sub>, 25 mM dNTPs, 500 nM each of forward and reverse amplification primer within the multiplex pool and 2.5 U HotStar Taq. dNTPs and primers were removed by incubation with 0.5 U shrimp alkaline phosphotase (SAP) at 37 °C for 40 minutes. SAP was inactivated by incubation at 87 °C for 5 minutes. Single base extension was carried out in 0.2X iPLEX buffer plus, 1X termination mix (containing mass modified termination nucleotides), 1X iPLEX enzyme and primers at 0.84 μM, 1.04 μM and 1.25 μM as appropriate to the relative mass of each primer. Following thermocycling, clean resin and water was added to the MassExtend reaction products. Samples were incubated in clean resin at room temperature with mixing for 5 minutes and centrifuged at 3200 × g for 5 minutes.</p>
<p id="P14">Samples were then dispensed to a SpectraChip using the MassArray Nanodispenser according to manufacturer’s instructions. Spectra chips were loaded into the MassArray analyzer and spectra acquired for each sample. Genotype calls were made using Typer 4.0 (Agena) by mass identification of extended primer peaks.</p>
</sec>
</sec>
</sec>
<sec id="S10">
<title>SNP Selection</title>
<sec id="S11">
<title>Development of Custom Array for Discovery Cohort</title>
<p id="P15">The process of selecting SNPs for the genotyping array involved two principal stages. First SNPs were amalgamated based on genetic signal for association to a small set of phenotypes (<xref ref-type="supplementary-material" rid="SD1">Table S14</xref>). The bulk of the SNPs were included on the basis of association results from four contrasts reported in three genome-wide studies: a contrast of AD+P versus AD-P,<sup><xref ref-type="bibr" rid="R29">29</xref></sup> AD+P versus controls,<sup><xref ref-type="bibr" rid="R29">29</xref></sup> AD versus controls <sup><xref ref-type="bibr" rid="R55">55</xref>;<xref ref-type="bibr" rid="R56">56</xref></sup>, and SCZ versus controls <sup><xref ref-type="bibr" rid="R32">32</xref>;<xref ref-type="bibr" rid="R57">57</xref></sup>. An additional unpublished data set (described in<sup><xref ref-type="bibr" rid="R58">58</xref>;<xref ref-type="bibr" rid="R59">59</xref></sup>) of cis-eQTLs affecting gene expression and cis-eQTLs associated with age-related changes in gene expression was also used. For the first four genome-wide association studies (GWAS), SNPs with p-value less than a threshold of 0.01 were selected; for the eQTLs, the threshold was 0.001 and for the ‘aging’ eQTLs it was 0.05. Note that when a SNP was represented in more than one study, the minimum p-value in any of the 6 datasets was taken as representative for the SNP. To interrogate copy number regions shown to be associated with schizophrenia, 1574 SNPs were included (1q21.1, 3q29, 15q11.2–15q13.3, 16p13.1, 16p11.2 and 22q11.2, recently reviewed in <sup><xref ref-type="bibr" rid="R60">60</xref></sup>; and 7q11.23<sup><xref ref-type="bibr" rid="R61">61</xref></sup>). Finally a small fraction of SNPs were chosen to cover four genes of interest regarding psychotic disorders (SCZ target genes: <italic>NRXN1</italic>,<sup><xref ref-type="bibr" rid="R60">60</xref></sup>
<italic>ERBB4</italic>,<sup><xref ref-type="bibr" rid="R62">62</xref></sup>
<italic>PAK2</italic>,<sup><xref ref-type="bibr" rid="R63">63</xref></sup>
<italic>CHRNA7</italic><sup><xref ref-type="bibr" rid="R64">64</xref></sup>) or were nominated from unpublished AD studies (UK SNPs).</p>
<p id="P16">Second, SNPs were retained for genotyping by a winnowing process. This process involved removing redundant SNPs, those that could not be genotyped on the Axiom platform, or SNPs not present in 1000 genomes. Of the SNPs passing this step, all SNPs with a minimum p-value &lt; 0.0001 for any study were retained. For the remainder, by using a LD clumping process, we removed SNPs in LD with the retained SNPs (r<sup>2</sup> &gt; 0.9) and retained additional SNPs with the smallest p-value in “independent” clumps (r<sup>2</sup> &lt; 0.9) by pruning SNPs with Plink (maximum distance for pruning was 5 kb, window width was 25 SNPs, sliding step was 5 SNPs).</p>
</sec>
<sec id="S12">
<title>SNP Selection for SCZ Risk Score Testing and Follow-up Genotyping in Replication Cohort</title>
<p id="P17">For SCZ risk score testing in each cohort we targeted the 128 GWA significant SNPs reported in <sup><xref ref-type="bibr" rid="R30">30</xref></sup>, although not all could be genotyped. Follow-up genotyping in the Replication Cohort also selected SNPs from our custom array that passed Quality Control and with P &lt; 0.0001 for the contrast of AD+P versus AD-P. For the replication cohort we selected Ancestry Informative Markers (AIMs) for European Ancestry based on the results in <sup><xref ref-type="bibr" rid="R65">65</xref></sup> Specifically, based on results found in with Supplementary Table 1 of Kosoy et al. <sup><xref ref-type="bibr" rid="R65">65</xref></sup>, we selected their “Top 96” European AIMs, of which 82 could be genotyped on the Sequenom platform and 79 passed Quality Control.</p>
</sec>
</sec>
<sec id="S13">
<title>Quality Control</title>
<p id="P18">QC was performed at the individual level first, then at the SNP level conditional on individual-level data passing QC and individuals of European ancestry. Details of QC are given in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material</xref>. In brief, genetic data for samples were retained if their nominal sex agreed with genetically determined sex; heterozygosity rate, per subject, revealed no evidence of contamination by other samples; genetic data for subjects expected to be unrelated suggested this were true; and call rate of SNPs &gt; 96.5% per sample. Next ancestry of subjects in the Discovery Cohort was determined using dacGem in GemTools based on 5712 autosomal markers with non-call rate ≤ 0.001, minor allele frequency (MAF) ≥ 0.05, and r<sup>2</sup> ≤ 0.20. The samples were separated into 5 clusters based on 3 significant ancestry dimensions, four of which likely represent European ancestry and two of these contain the bulk of the subjects (≈ 66%). SNP QC was performed on data from these two clusters. SNPs passed QC if their call rate was &gt; 95%, MAF was ≥ 0.01 and the exact Hardy Weinberg Equilibrium p-value was &gt; 0.005. Ancestry of samples in the Replication Cohort was determined using GemTools based on 79 autosomal Ancestry Informative Markers. The samples separated into 3 clusters based on 2 significant ancestry dimensions (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>).</p>
</sec>
<sec id="S14">
<title>Statistical Analysis</title>
<p id="P19">Association between diagnosis and minor allele count for each SNP was assessed using logistic regression. For the Discovery Cohort, the model also accounted for first 5 ancestry dimensions whereas for the Replication Cohort it accounted for two. Because some subjects in the Discovery Cohort were related as siblings, inference relied on the generalized estimating equation (gee) approach implemented in the statistical software R, assuming full siblings were correlated at 0.5 (i.e., twice the kinship coefficient for full siblings).</p>
<p id="P20">To predict affection status using polygenic risk scores, either unweighted or weighted risk scores could be computed: the unweighted score for a subject is the sum of the count of risk alleles over all genotypes for that subject; a weighted score uses the same principle, but the count of risk alleles per SNP is adjusted by a function of the estimated effect of the SNP on risk (log odds ratio). Both unweighted and weighted scores for AD+P risk were calculated. Scores were derived from results from the Discovery Cohort and then used to predict AD+P status based on genotypes for each subject in the Replication Cohort. For the SCZ-risk score, only a subset of the 128 GWA significant SNPs could be genotyped. For genotyped SNPs, an unweighted score for each AD subject was estimated.</p>
</sec>
</sec>
<sec id="S15" sec-type="results">
<title>Results</title>
<sec id="S16">
<title>Association of AD+P with novel common variants</title>
<p id="P21">Not all of the subjects genotyped on the Axiom array were independent of our previously reported GWAS meta-analysis.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> Of the 2876 Discovery Cohort subjects described in <xref ref-type="table" rid="T1">Table 1a</xref>, 1157 of these subjects were in our prior GWAS and the remainder, 1799 subjects (969 AD+P and 750 AD-P), were independent. We, therefore, evaluated association both as a joint analysis of the sample sets (mega-analysis) and by analysis of the independent subjects. For the former we use the traditional threshold for GWAS significance, 5×10<sup>−8</sup>; for the latter we used a somewhat more lenient threshold based sample sizes and the number of SNPs tested on both samples (5.6×10<sup>−8</sup>).</p>
<p id="P22">For neither the joint analysis (<xref ref-type="fig" rid="F2">Fig 2a</xref>) nor the independent analysis threshold (results not shown) was any SNP significantly associated with risk for AD+P. For the joint analysis there were 67 SNPs with P &lt; 5 × 10<sup>−4</sup> (<xref ref-type="fig" rid="F2">Fig 2a</xref>). To test these SNPs we empaneled a Replication Cohort (<xref ref-type="table" rid="T1">Table 1b</xref>). We successfully designed and assayed either the SNP or a proxy in perfect LD for 60/67 target SNPs.</p>
<p id="P23">We next used the results from the Discovery Cohort to assign the “risk allele” at each of the 60 SNPs. Then, by counting the number of risk alleles carried by subjects in the Replication Cohort, we formed an unweighted risk score for each subject. This score significantly predicted AD+P status in the Replication Cohort, showing clear evidence for association (<xref ref-type="table" rid="T2">Table 2a</xref>). The same is true for a weighted score (<xref ref-type="table" rid="T2">Table 2a</xref>).</p>
<p id="P24">Moreover, although no single SNP was significantly associated with risk for AD+P within or across stages, and only three SNPs approached individual significance when combining stages (<xref ref-type="fig" rid="F2">Fig 2b</xref> and <xref ref-type="table" rid="T3">Table 3</xref>), 41 out of the 60 SNPs had the same risk allele for both the Discovery and Replication Cohorts (<xref ref-type="fig" rid="F2">Fig 2b</xref>; Fisher Exact Test, p = 0.0062). The 3 SNPs that approached significance are in <italic>RP11-541P9.3</italic> (an antisense transcript) located 5′ to Cyclin G1 (<italic>CCNG1</italic>).</p>
</sec>
<sec id="S17">
<title>Association of AD+P with polygenic variation associated with schizophrenia</title>
<p id="P25">We previously described a significant association between AD+P and a summary statistic from a small number of putative schizophrenia and bipolar disorder risk alleles. Curiously, however, the direction of risk for most alleles was opposite in AD+P.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> Recently, 128 genome-wide significant SNPs at 108 independent loci have been identified in schizophrenia.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> When these loci were combined into a polygenic risk score they explained ~3.4% of the variance in schizophrenia risk.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> We successfully genotyped 101 of these SNPs in the Discovery Cohort. We found that the corresponding unweighted risk score was significantly associated with AD+P (Nagelkerke’s pseudo R<sup>2</sup> = 0.32%, P = 0.006). We then genotyped the schizophrenia SNPs in the Replication Cohort. For this analysis, 94 SNPs remained after QC. Results clearly replicated, with close agreement between the two cohorts (<xref ref-type="table" rid="T2">Table 2b</xref>).</p>
<p id="P26">Of note, as in our earlier report,<sup><xref ref-type="bibr" rid="R29">29</xref></sup> increasing schizophrenia polygenic risk score was associated with reduced risk of psychosis in AD. Consider, for example, its relationship within the Discovery Cohort. To better illustrate this relationship, we calculated an AD+P aligned risk score. For each of the SNPs comprising the schizophrenia polygenic risk score, the allele that increased the risk of developing AD+P was determined and a weighted sum of risks was then computed for each of the samples. The correlation between the AD+P aligned risk scores and the schizophrenia risk scores was −0.159 (p = 5.5e-18, <xref ref-type="fig" rid="F3">Fig 3</xref>).</p>
<p id="P27">It should be noted that despite the overall protective effects of schizophrenia polygenic risk score on AD+P risk, a smaller number of individual schizophrenia risk SNPs were associated with increased risk of AD+P. <xref ref-type="table" rid="T4">Table 4a</xref> details the 20 SNPs that most consistently (as defined by the minimum of the sum of their individual SNP regression coefficients from the analysis of the Discovery and Replication cohorts) were associated with reduced AD+P risk. <xref ref-type="table" rid="T4">Table 4b</xref> provides similar information for the 10 SNPs that most consistently were associated with increased AD+P risk in the two cohorts.</p>
</sec>
</sec>
<sec id="S18" sec-type="discussion">
<title>Discussion</title>
<p id="P28">Psychosis occurs in approximately half of individuals affected by AD, serving to identify a subgroup with more rapid decline and poor outcomes. We, and others, have hypothesized that common genetic variation may contribute to the risk of psychosis in AD, based in part on evidence that AD+P aggregates in families, with an estimated heritability of 61%. However, prior studies of the association of common genetic variation with AD+P have been inconclusive.<sup><xref ref-type="bibr" rid="R66">66</xref>;<xref ref-type="bibr" rid="R67">67</xref></sup> We now provide the first clear evidence in support of an association of AD+P with both a unique set of common variants, and with a set of common variants associated with risk for schizophrenia.</p>
<p id="P29">Several potential methodologic issues in determining the psychosis phenotype are important to consider in evaluating our findings. First, the need to aggregate multiple cohorts so as to have sufficient power for detection of association with common genetic variation meant that we included sites in which different rating scales were used for ascertainment of psychosis, which could have contributed noise to our phenotypic classifications. Such a limitation, if present, would have reduced our power to detect differences between groups. Thus, it speaks to the robustness of our findings that despite this potential limitation, we were able to replicate associations across two independent, somewhat heterogeneous cohorts. Perhaps this result is not surprising, in that significant familial aggregation of AD+P was previously identified in three separate family cohorts, each of which relied primarily on a different behavioral rating scale.<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R25">25</xref>;<xref ref-type="bibr" rid="R26">26</xref></sup> Second, we chose to consider delusions and hallucinations together as a psychosis syndrome rather than evaluate them individually. The best approach to this issue likely depends on the question being asked. For example, when evaluating functional neuroanatomy separation of these symptoms could make most sense. However, for genetic studies, there is substantial support for grouping these symptoms. Specifically, studies demonstrating familial aggregation of AD+P<sup><xref ref-type="bibr" rid="R4">4</xref>;<xref ref-type="bibr" rid="R25">25</xref>;<xref ref-type="bibr" rid="R26">26</xref></sup> have all used this joint definition, establishing it as suitable for genetic investigation. Similar data in support of individual psychotic symptoms does not exist. Finally, the relationships between clinical Dementia with Lewy Body diagnoses (DLB), Lewy Body neuropathology, and AD+P is complex.<sup><xref ref-type="bibr" rid="R67">67</xref>;<xref ref-type="bibr" rid="R68">68</xref></sup> In brief, DLB pathology may contribute to some proportion, but clearly not account for most, of the occurrence of AD+P. Nevertheless, all sites in the current study used standard diagnostic criteria to identify individuals with probable Lewy Body Dementia and exclude them from analysis (the one exception being the NIMH family study which predated the generation of DLB criteria, but did exclude individuals with parkinsonism or prominent early behavioral disturbance.<sup><xref ref-type="bibr" rid="R69">69</xref></sup> As practical evidence that these diagnostic approaches are sufficiently rigorous to identify AD separately from DLB, the sites included in the current study have successfully contributed to discovery of common variants for AD risk.<sup><xref ref-type="bibr" rid="R42">42</xref></sup></p>
<p id="P30">We identified a set of SNPs with suggestive association with AD+P in our Discovery Cohort, confirming this polygenic association with AD+P in an independent Replication Cohort. Although no individual SNP reached genome-wide significance in the meta-analysis, the strongest associations were seen with three SNPs, rs300215, rs6859958 and rs999581, within a single locus. The function of the antisense transcript, <italic>RP11-541P9.3</italic>, is not known. However, it is located 5′ to <italic>CCNG1</italic> and is therefore likely to regulate <italic>CCNG1</italic> expression. In support of this interpretation, rs6859958 and rs999581 have been shown to be eQTLs for <italic>CCNG1</italic> in some tissues.<sup><xref ref-type="bibr" rid="R70">70</xref></sup> Most cyclins activate cyclin dependent kinases, including <italic>CDK5</italic>, a Tau kinase that promotes phospho-Tau aggregation.<sup><xref ref-type="bibr" rid="R71">71</xref></sup> In contrast, <italic>CCNG1</italic> has been proposed to competitively inhibit the activation of cyclin dependent kinases by other cyclins.<sup><xref ref-type="bibr" rid="R72">72</xref></sup> Whether increased levels of Cyclin G1, the protein product of <italic>CCNG1</italic>, is therefore protective against pathological phosphorylation of Tau by CDK5 is not established. Nonetheless, in neocortex of AD subjects Cyclin G1 levels are increased in pyramidal neurons lacking Tau aggregates and are undetectable in those pyramidal neurons containing aggregated phospho-Tau.<sup><xref ref-type="bibr" rid="R73">73</xref></sup> Because the strongest brain correlate of psychosis in AD is excess phosphorylation of tau (in comparison to the degree of Tau phosphorylation in AD subjects without psychosis),<sup><xref ref-type="bibr" rid="R67">67</xref></sup>
<italic>CCNG1</italic> is thus also a strong functional candidate for AD+P risk.</p>
<p id="P31">We also identified and confirmed an association of polygenic risk for schizophrenia with a reduced risk of AD+P. At present, there is little convergent data from family studies to inform on the relationship of schizophrenia risk to AD+P.<sup><xref ref-type="bibr" rid="R9">9</xref>;<xref ref-type="bibr" rid="R74">74</xref></sup> The inverse nature of the association between schizophrenia risk score and AD+P may seem counterintuitive at first. In fact, it was the counterintuitive nature of our findings that motivated us to attempt to independently replicate them, finding a nearly identical association in a second large cohort. In contrast to our findings, schizophrenia has been shown to share polygenic risk with a number of complex disorders, such as autism and bipolar illness, which may include psychotic symptoms as part of the expressed phenotype.<sup><xref ref-type="bibr" rid="R75">75</xref></sup> Unlike AD+P, these are disorders of early, or late, neurodevelopment and thus do not occur in the context of neurodegeneration.</p>
<p id="P32">Possible genetic mechanisms underlying how the 108 schizophrenia-associated loci confer an increased risk of schizophrenia are just now emerging.<sup><xref ref-type="bibr" rid="R76">76</xref>–<xref ref-type="bibr" rid="R78">78</xref></sup> How these loci may lead to reduced AD+P risk cannot be asserted, but a few exemplars are worth discussion. First, a locus may alter expression of a single gene that has effects during neurodevelopment which increase schizophrenia risk, but when the same altered expression occurs in a brain with an active AD neurodegenerative process, it is protective. For example, rs75968099 is an eQTL for <italic>LRRFIP2</italic> (<xref ref-type="table" rid="T4">Table 4</xref>), the gene encoding Leucine-rich Repeat Flightless-interacting Protein 2, a regulator of Toll-like receptor 4-mediated signaling in response to inflammatory stimuli. Toll-like receptor 4 signaling helps activate microglia to clear toxic amyloid β from the brain of an AD patient in early disease stages,<sup><xref ref-type="bibr" rid="R79">79</xref></sup> whereas microglial activation may contribute to excess synaptic elimination in development, increasing risk for schizophrenia.<sup><xref ref-type="bibr" rid="R76">76</xref></sup> Second, a locus may regulate the expression of gene transcription differently during early neurodevelopment than in the adult brain. Such an effect has recently been described for the schizophrenia risk locus defined by rs55833108, and may similarly be present at loci that confer opposing risks for schizophrenia and AD+P.<sup><xref ref-type="bibr" rid="R78">78</xref></sup> A third scenario might result from the observation that a SNP and/or locus may be an eQTL for more than one gene. For example, the locus on chromosome 17 defined by rs8082590 was recently reported to show consistent disease and eQTL associations for two genes, <italic>TOM1L2</italic> and <italic>DRG2</italic>,<sup><xref ref-type="bibr" rid="R77">77</xref></sup> encoding Target Of Myb1 Like 2 Membrane Trafficking Protein and Developmentally Regulated GTP Binding Protein 2, respectively. Developmentally Regulated GTP Binding Protein 2 deactivates the early endosome regulator, Ras-related protein Rab-5A.<sup><xref ref-type="bibr" rid="R80">80</xref></sup> Thus it is strongly positioned to impact glutamate neurotransmission, a process implicated in the pathogenesis of schizophrenia, via effects on neurotransmitter release<sup><xref ref-type="bibr" rid="R81">81</xref></sup> and on AMPA receptor internalization.<sup><xref ref-type="bibr" rid="R82">82</xref></sup> In contrast, Target Of Myb1 Like 2 Membrane Trafficking Protein is necessary for delivery of endosome cargo to autophagosomes, which target protein aggregates and damaged organelles to lysosomes for degradation.<sup><xref ref-type="bibr" rid="R83">83</xref></sup> The autophagy pathway is strongly implicated in the pathogenesis of AD<sup><xref ref-type="bibr" rid="R84">84</xref></sup> and, more recently, of schizophrenia,<sup><xref ref-type="bibr" rid="R85">85</xref></sup> and is also downstream of Toll-like receptor 4 signaling.<sup><xref ref-type="bibr" rid="R86">86</xref></sup> Finally, we note that the above examples are not comprehensive. Other mechanisms may also contribute to different impacts of loci on risk for schizophrenia and AD+P.</p>
<p id="P33">As indicated in <xref ref-type="table" rid="T4">Table 4b</xref>, we also identified SNPs that showed the same direction of effect for schizophrenia and AD+P risk, Notable among these were two intronic SNPs located in <italic>CACNA1C</italic>, the gene encoding the voltage-dependent L-type calcium channel subunit alpha-1C. Although the genetic mechanism underlying these associations remains an area of active inquiry,<sup><xref ref-type="bibr" rid="R87">87</xref></sup> convergent data suggests that schizophrenia is associated with reduced voltage-dependent calcium channel function.<sup><xref ref-type="bibr" rid="R88">88</xref>–<xref ref-type="bibr" rid="R90">90</xref></sup> How reductions in voltage-dependent calcium channel function may further increase AD+P risk is not known, however, impairments of intracellular Ca<sup>2+</sup> homeostasis are present in AD, and can contribute to synaptic dysfunction and cognitive impairments.<sup><xref ref-type="bibr" rid="R91">91</xref></sup></p>
<p id="P34">We recently estimated the annual incidence of psychosis in AD at 10%.<sup><xref ref-type="bibr" rid="R40">40</xref></sup> Thus there is an opportunity to intervene prior to psychosis onset if individual predictors can be identified. Although currently no treatments are established for prevention of AD+P, selective serotonin reuptake inhibitors have some efficacy for treating it,<sup><xref ref-type="bibr" rid="R22">22</xref>;<xref ref-type="bibr" rid="R23">23</xref></sup> and they have acceptable tolerability. Non-pharmacologic treatments may also offer benefit for treating AD+P (reviewed in<sup><xref ref-type="bibr" rid="R92">92</xref> and<xref ref-type="bibr" rid="R40">40</xref></sup>) and could be adapted for prevention. It is thus worth considering whether genetic variants that associate with psychosis may serve as biomarkers to predict AD+P risk and the associated more rapidly declining cognitive trajectory. Because individual SNP relative risks are typically small, polygenic risk scores have greater predictive power.<sup><xref ref-type="bibr" rid="R31">31</xref>;<xref ref-type="bibr" rid="R93">93</xref></sup> We observed a very modest explanatory power of both the 60 SNP and the schizophrenia polygenic risk scores, each accounting for less than 1% of the AD+P risk. None of these effects is large enough to yield meaningful clinical prediction at present. Still we note that these polygenic scores could have a different magnitude of effect on prediction of a related, clinically relevant construct, such as time to onset of psychosis. However, the development of predictive approaches would clearly benefit from the identification of additional risk loci. Nevertheless, the current findings are a step forward in the development of prevention for psychosis in AD.</p>
<p id="P35">In that regard it is noteworthy that our custom array, used to evaluate the Discovery Cohort, was derived, in part, from the one existing GWAS of AD+P. That earlier GWAS was underpowered and limited in the number of loci interrogated.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> As a consequence it is likely that many SNPs and loci that contribute meaningfully to AD+P risk were not tested in the current study. Despite this limitation, the current study provides confirmation of the hypothesis that AD+P is associated with common genetic variation. As such, it provides strong support for unbiased genome-wide scans of larger cohorts of AD+P and AD-P subjects, which will surely identify individual AD+P risk loci and develop more strongly predictive polygenic risk scores.</p>
</sec>
<sec id="S19" sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>1</label>
<media id="d36e1145" orientation="portrait" position="anchor" xlink:href="NIHMS855614-supplement-1.docx" xlink:type="simple"></media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S20">
<p>This study was supported by the following federal grants: AG027224 (RAS), AG005133 (RAS), BX000452 (RAS), MH057881 (BD), AG030653 (MIK), AG041718(MIK), and MH093723 (ELS). This project used the University of Pittsburgh HSCRF Genomics Research Core iPlex and Specimen Processing services. Cardiff University was supported by the Wellcome Trust, Medical Research Council (MRC) and/or Alzheimer’s Research UK (ARUK) and the Welsh Assembly Government (RS &amp; JW).</p>
<p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government.</p>
</ack>
<fn-group>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflict of Interest:</bold> MAAD-S, EAW, LK, DJH, DTV, DJH, HJS, RS, TF, IH, SM-G, LT, MB, AR, JW, RM, OLL, ELS, MIK, BD, and RAS have no conflicts to report.</p>
</fn>
</fn-group>
<ref-list>
<title>Reference List</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ropacki</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</name>
</person-group>
<article-title>Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003</article-title>
<source/>Am J Psychiatry
          <year>2005</year>
<volume>162</volume>
<fpage>2022</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">16263838</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weamer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Emanuel</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Varon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miyahara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wilkosz</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The relationship of excess cognitive impairment in MCI and early Alzheimer’s disease to the subsequent emergence of psychosis</article-title>
<source/>Int Psychogeriatr
          <year>2009</year>
<volume>21</volume>
<fpage>78</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">18814807</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuel</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Houck</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Weamer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2011</year>
<volume>19</volume>
<fpage>160</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">20808116</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s Disease Family Study</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<fpage>1155</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">20147454</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seltman</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>A Bayesian model of psychosis symptom trajectory in Alzheimer’s disease</article-title>
<source/>Int J Geriatr Psychiatry
          <year>2016</year>
<volume>31</volume>
<fpage>204</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">26216660</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Seltman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Emanuel</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Bis</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of Alzheimer’s disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study</article-title>
<source/>Am J Psychiatry
          <year>2012</year>
<volume>169</volume>
<fpage>954</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">22952074</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koppel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sunday</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Christen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Greenwald</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Psychosis in Alzheimer’s disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer’s Disease Neuroimaging Initiative</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2014</year>
<volume>22</volume>
<fpage>698</fpage>
<lpage>707</lpage>
<pub-id pub-id-type="pmid">23672944</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koppel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Keehlisen</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2012</year>
<volume>20</volume>
<fpage>994</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="pmid">22048323</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilley</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Whalen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Hallucinations and associated factors in Alzheimer’s disease</article-title>
<source/>J Neuropsychiatry
          <year>1991</year>
<volume>3</volume>
<fpage>371</fpage>
<lpage>76</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilley</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Beckett</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Psychotic symptoms and physically aggressive behavior in Alzheimer’s disease</article-title>
<source/>J Am Geriatr Soc
          <year>1997</year>
<volume>45</volume>
<fpage>1074</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">9288014</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Sukonick</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Mulsant</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klunk</surname>
<given-names>WE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer’s disease</article-title>
<source/>Int Psychogeriatr
          <year>2001</year>
<volume>13</volume>
<fpage>401</fpage>
<lpage>09</lpage>
<pub-id pub-id-type="pmid">12003247</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufer</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Christine</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Castellon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Masterman</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale</article-title>
<source/>J Am Geriatr Soc
          <year>1998</year>
<volume>46</volume>
<fpage>210</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">9475452</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarmeas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hadjigeorgiou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Papadimitriou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Delusions and hallucinations are associated with worse outcome in Alzheimer disease</article-title>
<source/>Arch Neurol
          <year>2005</year>
<volume>62</volume>
<fpage>1601</fpage>
<lpage>08</lpage>
<pub-id pub-id-type="pmid">16216946</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabins</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Mace</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>The impact of dementia on the family</article-title>
<source/>JAMA
          <year>1982</year>
<volume>248</volume>
<fpage>333</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">7087127</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Boller</surname>
<given-names>F</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease</article-title>
<source/>Arch Neurol
          <year>1999</year>
<volume>56</volume>
<fpage>1266</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">10520944</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bianchetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Trabucchi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Risk of mortality and institutionalization in demented patients with delusions</article-title>
<source/>J Geriatr Psychiatry Neurol
          <year>1996</year>
<volume>9</volume>
<fpage>123</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">8873875</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Litvan</surname>
<given-names>II</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric Syndromes in Neurodegenerative Disease: Frequency and Signficance</article-title>
<source/>Semin Clin Neuropsychiatry
          <year>1996</year>
<volume>1</volume>
<fpage>241</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">10320427</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassiony</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosenblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lyketsos</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Delusions and hallucinations in Alzheimer’s disease: Prevalence and clinical correlates</article-title>
<source/>Int J Geriatr Psychiatry
          <year>2000</year>
<volume>15</volume>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">10679840</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Gilley</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Mccann</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bienias</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hallucinations, cognitive decline, and death in Alzheimer’s disease</article-title>
<source/>Neuroepidemiology
          <year>2006</year>
<volume>26</volume>
<fpage>68</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">16352909</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Dagerman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Insel</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2006</year>
<volume>14</volume>
<fpage>191</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">16505124</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huybrechts</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Gerhard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Crystal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Olfson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Avorn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study</article-title>
<source/>BMJ
          <year>2012</year>
<volume>344</volume>
<fpage>e977</fpage>
<pub-id pub-id-type="pmid">22362541</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollock</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Mulsant</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mazumdar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bharucha</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized, double-blind, placebo-controlled comparison of citalopram and perphenazine for the acute treatment of psychosis and behavioral disturbances associated with dementia</article-title>
<source/>Am J Psychiatry
          <year>2002</year>
<volume>159</volume>
<fpage>460</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">11870012</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonpacher</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Drye</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Makino</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Newell</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Devanand</surname>
<given-names>DP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD Study</article-title>
<source/>Am J Psychiatry
          <year>2016</year>
<volume>173</volume>
<fpage>473</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">27032628</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kales</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Valenstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Ganoczy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications</article-title>
<source/>Am J Psychiatry
          <year>2007</year>
<volume>164</volume>
<fpage>1568</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">17898349</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Increased familial risk of the psychotic phenotype of Alzheimer disease</article-title>
<source/>Neurology
          <year>2002</year>
<volume>58</volume>
<fpage>907</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">11914406</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollingworth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamshere</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Holmans</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased familial risk and genomewide significant linkage for Alzheimer’s disease with psychosis</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2007</year>
<volume>144B</volume>
<fpage>841</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">17492769</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacanu</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chowdari</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Heritability of psychosis in Alzheimer disease</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2005</year>
<volume>13</volume>
<fpage>624</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">16009739</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barral</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vardarajan</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Reyes-Dumeyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Faber</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants associated with susceptibility to psychosis in late-onset Alzheimer’s disease families</article-title>
<source/>Neurobiol Aging
          <year>2015</year>
<volume>36</volume>
<fpage>3116</fpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollingworth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harold</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association study of Alzheimer’s disease with psychotic symptoms</article-title>
<source/>Mol Psychiatry
          <year>2012</year>
<volume>17</volume>
<fpage>1316</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">22005930</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>
<source/> Nature
          <year>2014</year>
<volume>511</volume>
<fpage>421</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">25056061</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wray</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Visscher</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common polygenic variation contributes to risk of schizophrenia and bipolar disorder</article-title>
<source/>Nature
          <year>2009</year>
<volume>460</volume>
<fpage>748</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">19571811</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<article-title>Genome-wide association study identifies five new schizophrenia loci</article-title>
<source/>Nat Genet
          <year>2011</year>
<volume>43</volume>
<fpage>969</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">21926974</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bacchelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Individual common variants exert weak effects on the risk for autism spectrum disorders</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<fpage>4781</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">22843504</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Los</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Fernando</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Klimentidis</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Prediction of complex human traits using the genomic best linear unbiased predictor</article-title>
<source/>PLoS Genet
          <year>2013</year>
<volume>9</volume>
<fpage>e1003608</fpage>
<pub-id pub-id-type="pmid">23874214</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazquez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Klimentidis</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Dhurandhar</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Veturi</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Paerez-Rodriguez</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Assessment of whole-genome regression for type II diabetes</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0123818</fpage>
<pub-id pub-id-type="pmid">25885636</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKhann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Drachman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stadlan</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease</article-title>
<source/>Neurology
          <year>1984</year>
<volume>34</volume>
<fpage>939</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">6610841</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirra</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Heyman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McKeel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sumi</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Brownlee</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II Standardization of the neuropathologic assessment of Alzheimer’s disease</article-title>
<source/>Neurology
          <year>1991</year>
<volume>41</volume>
<fpage>479</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">2011243</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKeith</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Emre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>1863</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">16237129</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferrell</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Weamer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Emanuel</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>No association of psychosis in Alzheimer disease with neurodegenerative pathway genes</article-title>
<source/>Neurobiol Aging
          <year>2011</year>
<volume>32</volume>
<fpage>555</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weamer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cloonan</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer’s Disease</article-title>
<source/>J Clin Psychiatry
          <year>2016</year>
<volume>77</volume>
<fpage>e1564</fpage>
<lpage>e1569</lpage>
<pub-id pub-id-type="pmid">28086011</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Ikram</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>DeStefano</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Gudnason</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Boada</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>
<source/>JAMA
          <year>2010</year>
<volume>303</volume>
<fpage>1832</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">20460622</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ibrahim-Verbaas</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Harold</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Naj</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bellenguez</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>1452</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">24162737</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Hatch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>BC</given-names>
</name>
</person-group>
<article-title>Zung, Beck, and Hamilton Rating Scales as measures of treatment outcome: A meta-analytic comparison</article-title>
<source/>J Consult Clin Psychol
          <year>1986</year>
<volume>54</volume>
<fpage>54</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">3958302</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Psychosis in Alzheimer’s disease in the national Alzheimer’s disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e</article-title>
<source/>Int J Alzheimers Dis
          <year>2011</year>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tariot</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Mack</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Edland</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Fillenbaum</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer’s Disease</article-title>
<source/>Am J Psychiatry
          <year>1995</year>
<volume>152</volume>
<fpage>1349</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">7653692</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufer</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Ketchel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>V</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shelley</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory</article-title>
<source/>J Neuropsychiatry Clin Neurosci
          <year>2000</year>
<volume>12</volume>
<fpage>233</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">11001602</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cejudo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Tarraga</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Kaufer</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric Inventory Questionnaire (NPI-Q): Spanish validation of a brief clinical form of the Neuropsychiatric inventory (NPI)</article-title>
<source/>Neurologia
          <year>2002</year>
<volume>17</volume>
<fpage>317</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">12084358</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mega</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rosenberg-Thompson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carusi</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gornbein</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title>
<source/>Neurology
          <year>1994</year>
<volume>44</volume>
<fpage>2308</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">7991117</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Overall</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Gorham</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>The brief psychiatric rating scale</article-title>
<source/>Psychol Rep
          <year>1962</year>
<volume>10</volume>
<fpage>799</fpage>
<lpage>812</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubenko</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mulsant</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Impact of psychiatric hospitalization on behavioral complications of Alzheimer’s disease</article-title>
<source/>Am J Psychiatry
          <year>1992</year>
<volume>149</volume>
<fpage>1484</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">1357991</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Danziger</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Coben</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>A new clinical scale for the staging of dementia</article-title>
<source/>Br J Psychiatry
          <year>1982</year>
<volume>140</volume>
<fpage>566</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">7104545</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folstein</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>McHugh</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>“Mini-mental state” A practical method for grading the cognitive state of patients for the clinician</article-title>
<source/>J Psychiatr” Res
          <year>1975</year>
<volume>12</volume>
<fpage>189</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">1202204</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacanu</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chowdari</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Linkage analysis of Alzheimer disease with psychosis</article-title>
<source/>Neurology
          <year>2002</year>
<volume>59</volume>
<fpage>118</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">12105318</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<source/>Affymetrix axiom assay user manual
          <year>2016</year>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naj</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beecham</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Vardarajan</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Buros</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease</article-title>
<source/>Nat Genet
          <year>2011</year>
<volume>43</volume>
<fpage>436</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">21460841</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="web">
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.niagads.org/dataset/ng00027">https://www.niagads.org/dataset/ng00027</ext-link>
</comment>
<year>2016</year>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<source/>SCZ1 Dataset
          <year>2016</year>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Kirkwood</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sibille</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer’s Disease Pathways</article-title>
<source/>Front Psychiatry
          <year>2015</year>
<volume>6</volume>
<fpage>30</fpage>
<pub-id pub-id-type="pmid">25806004</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seney</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Role of Genetic Sex in Affect Regulation and Expression of GABA-Related Genes Across Species</article-title>
<source/>Front Psychiatry
          <year>2013</year>
<volume>4</volume>
<fpage>104</fpage>
<pub-id pub-id-type="pmid">24062698</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>CNVs in neuropsychiatric disorders</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<fpage>R45</fpage>
<lpage>R49</lpage>
<pub-id pub-id-type="pmid">26130694</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulle</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Pulver</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wolyniec</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11. 23 is associated with schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>371</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">23871472</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banerjee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Borgmann-Winter</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome</article-title>
<source/>Brain Res Bull
          <year>2010</year>
<volume>83</volume>
<fpage>132</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">20433909</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulle</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wolyniec</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microdeletions of 3q29 confer high risk for schizophrenia</article-title>
<source/>Am J Hum Genet
          <year>2010</year>
<volume>87</volume>
<fpage>229</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">20691406</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cloninger</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7)</article-title>
<source/>Am J Med Genet
          <year>2001</year>
<volume>105</volume>
<fpage>20</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">11424985</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosoy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nassir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>C</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America</article-title>
<source/>Hum Mutat
          <year>2009</year>
<volume>30</volume>
<fpage>69</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">18683858</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Genetics of psychosis in Alzheimer’s disease: a review</article-title>
<source/>J Alzheimers Dis
          <year>2010</year>
<volume>19</volume>
<fpage>761</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">20157235</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>DeMichele-Sweet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Psychosis in Alzheimer’s Disease</article-title>
<source/>Biol Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>542</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">24103379</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</name>
</person-group>
<article-title>Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype</article-title>
<source/>Mol Psychiatry
          <year>2003</year>
<volume>8</volume>
<fpage>383</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">12740595</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blacker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Harrell</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. The National Institute of Mental Health Genetics Initiative</article-title>
<source/>Arch Neurol
          <year>1994</year>
<volume>51</volume>
<fpage>1198</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">7986174</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westra</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Esko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yaghootkar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schurmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kettunen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systematic identification of trans eQTLs as putative drivers of known disease associations</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>1238</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">24013639</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkaniec</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Czapski</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Adamczyk</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>136</volume>
<fpage>222</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">26376455</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Cyclin G is a transcriptional target of the p53 tumor suppressor protein</article-title>
<source/>EMBO J
          <year>1994</year>
<volume>13</volume>
<fpage>4816</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">7957050</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jordan-Sciutto</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bowser</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Increased Cyclin G1 Immunoreactivity During Alzheimer’s Disease</article-title>
<source/>J Alzheimers Dis
          <year>1999</year>
<volume>1</volume>
<fpage>409</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">12214116</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotrla</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Chacko</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Clinical variables associated with psychosis in Alzheimer’s disease</article-title>
<source/>Am J Psychiatry
          <year>1995</year>
<volume>152</volume>
<fpage>1377</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">7653698</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoller</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>1371</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">23453885</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bialas</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>de Rivera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Kamitaki</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schizophrenia risk from complex variation of complement component 4</article-title>
<source/>Nature
          <year>2016</year>
<volume>530</volume>
<fpage>177</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">26814963</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sieberts</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Perumal</surname>
<given-names>TM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression elucidates functional impact of polygenic risk for schizophrenia</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<fpage>1442</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">27668389</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24. 2 schizophrenia-associated locus</article-title>
<source/>Nat Med
          <year>2016</year>
<volume>22</volume>
<fpage>649</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">27158905</pub-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gambuzza</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sofo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Salmeri</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Soraci</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Toll-like receptors in Alzheimer’s disease: a therapeutic perspective</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2014</year>
<volume>13</volume>
<fpage>1542</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">25106635</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>UH</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Seol</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmentally regulated GTP-binding protein 2 coordinates Rab5 activity and transferrin recycling</article-title>
<source/>Mol Biol Cell
          <year>2016</year>
<volume>27</volume>
<fpage>334</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">26582392</pub-id>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wucherpfennig</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wilsch-Brauninger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gonzalez-Gaitan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Role of Drosophila Rab5 during endosomal trafficking at the synapse and evoked neurotransmitter release</article-title>
<source/>J Cell Biol
          <year>2003</year>
<volume>161</volume>
<fpage>609</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">12743108</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Backos</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Esteban</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD</article-title>
<source/>Neuron
          <year>2005</year>
<volume>45</volume>
<fpage>81</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">15629704</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tumbarello</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Waxse</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Arden</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Bright</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Kendrick-Jones</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buss</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Autophagy receptors link myosin VI to autophagosomes to mediate Tom1-dependent autophagosome maturation and fusion with the lysosome</article-title>
<source/>Nat Cell Biol
          <year>2012</year>
<volume>14</volume>
<fpage>1024</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">23023224</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Autophagy dysfunction in Alzheimer’s disease</article-title>
<source/>Neurodegener Dis
          <year>2010</year>
<volume>7</volume>
<fpage>265</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">20551691</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merenlender-Wagner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Malishkevich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shemer</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Udawela</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scarr</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autophagy has a key role in the pathophysiology of schizophrenia</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>126</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">24365867</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jagannath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>XD</given-names>
</name>
<name>
<surname>Sharafkhaneh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kolodziejska</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Eissa</surname>
<given-names>NT</given-names>
</name>
</person-group>
<article-title>Toll-like receptor 4 is a sensor for autophagy associated with innate immunity</article-title>
<source/>Immunity
          <year>2007</year>
<volume>27</volume>
<fpage>135</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">17658277</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckart</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McCallion</surname>
<given-names>AS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional Characterization of Schizophrenia-Associated Variation in CACNA1C</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<fpage>e0157086</fpage>
<pub-id pub-id-type="pmid">27276213</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Solovieff</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title>
<source/>Nature
          <year>2014</year>
<volume>506</volume>
<fpage>185</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">24463508</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yorgan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lipscombe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>JQ</given-names>
</name>
</person-group>
<article-title>A rare schizophrenia risk variant of CACNA1I disrupts CaV3 channel activity</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>34233</fpage>
<pub-id pub-id-type="pmid">27756899</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macdonald</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Alhassan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Fish</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Penzes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wills</surname>
<given-names>ZP</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Selective Loss of Smaller Spines in Schizophrenia</article-title>
<source/>Am J Psychiatry
          <year>2017</year>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Briggs</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Chakroborty</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stutzmann</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Emerging pathways driving early synaptic pathology in Alzheimer’s disease</article-title>
<source/>Biochem Biophys Res Commun
          <year>2017</year>
<volume>483</volume>
<fpage>988</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">27659710</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geda</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Gitlin</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future</article-title>
<source/>Alzheimers Dement
          <year>2013</year>
<volume>9</volume>
<fpage>602</fpage>
<lpage>08</lpage>
<pub-id pub-id-type="pmid">23562430</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corvin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Craddock</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Genome-wide association studies: a primer</article-title>
<source/>Psychol Med
          <year>2010</year>
<volume>40</volume>
<fpage>1063</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">19895722</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Diagram of the study design and workflow</title>
<p>Abbreviations used: ACE: Fundació ACE Barcelona Alzheimer Treatment and Research Center; ADRC: University of Pittsburgh Alzheimer Disease Research Center; NIA LOAD: National Institute on Aging’s Late Onset Alzheimer’s Disease Family Study; NIMH: National Institute of Mental Health Genetics Initiative AD Cohort; UK: Genetic and Environmental Risk in AD Consortium 1; ADC: consortium of National Institute on Aging Alzheimer Disease Centers; CHS: Cardiovascular Health Study; AD-P: Alzheimer disease without psychosis; AD+P: Alzheimer disease with psychosis; SCZ: schizophrenia; GWAS: Genome-wide association study</p>
</caption>
<graphic xlink:href="nihms855614f1"></graphic>
</fig>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Discovery (a) and replication (b) analysis of AD+P risk SNPs</title>
<p><bold>A.</bold> 67 SNPs reached p &lt; 5e-4 in Stage 2 samples (dashed line). <bold>B.</bold> Stage 3 examined 60 of the 67 SNPS, three of which (top blue circles, <xref ref-type="table" rid="T3">Table 3</xref>) approached significance in meta-analysis (P = 1.61×10<sup>−6</sup>). In blue, SNPs showing same risk allele in Stages 2 and 3; red, Stage 2 versus 3 results differ in sign (risk allele); size of circle reflects meta-analysis −log<sub>10</sub>(P).</p>
</caption>
<graphic xlink:href="nihms855614f2"></graphic>
</fig>
<fig id="F3" orientation="portrait" position="float">
<label>Fig. 3</label>
<caption>
<title>Relationship between schizophrenia risk score and risk of psychosis in AD</title>
<p>Displayed are the risk scores for each subject, the score for schizophrenia uses the allele found to confer risk in <sup><xref ref-type="bibr" rid="R30">30</xref></sup>, whereas the AD+P aligned score uses the same SNPs but assigns risk according to the AD+P association results. Red and blue circles indicate AD+P and AD-P subjects, respectively.</p>
</caption>
<graphic xlink:href="nihms855614f3"></graphic>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Cohort subject characteristics.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="1" rowspan="1" valign="top">AD-P<break></break>N(%) or Mean (SD)</th>
<th align="center" colspan="1" rowspan="1" valign="top">AD+P<break></break>N(%) or Mean (SD)</th>
<th align="center" colspan="1" rowspan="1" valign="top">Total<break></break>N (%) or Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<bold>A. Discovery Cohort</bold>
</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>N</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">1115 (38.8)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1761 (61.2)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2876 (100)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Female</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">722 (64.8)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1262 (71.7)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1984 (69.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>AOO</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">75.5 (7.8)</td>
<td align="center" colspan="1" rowspan="1" valign="top">74.1 (7.3)</td>
<td align="center" colspan="1" rowspan="1" valign="top">74.6 (7.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Age</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">80.6 (7.3)</td>
<td align="center" colspan="1" rowspan="1" valign="top">81.0 (6.8)</td>
<td align="center" colspan="1" rowspan="1" valign="top">80.8 (7.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Last MMSE</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">14.6 (6.7)</td>
<td align="center" colspan="1" rowspan="1" valign="top">12.0 (7.2)</td>
<td align="center" colspan="1" rowspan="1" valign="top">13.2 (7.1)</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<bold>B. Replication Cohort</bold>
</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>N</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">1460 (66.5)</td>
<td align="center" colspan="1" rowspan="1" valign="top">734 (33.5)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2194 (100)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Female</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">905 (62.0)</td>
<td align="center" colspan="1" rowspan="1" valign="top">496 (67.6)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1401 (63.8)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>AOO</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">74.6 (8.2)</td>
<td align="center" colspan="1" rowspan="1" valign="top">74.7 (7.4)</td>
<td align="center" colspan="1" rowspan="1" valign="top">74.6 (8.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Age</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">80.5 (7.8)</td>
<td align="center" colspan="1" rowspan="1" valign="top">81.2 (7.1)</td>
<td align="center" colspan="1" rowspan="1" valign="top">80.7 (7.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Last MMSE</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">16.6 (6.6)</td>
<td align="center" colspan="1" rowspan="1" valign="top">14.3 (7.4)</td>
<td align="center" colspan="1" rowspan="1" valign="top">15.9 (6.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p>AD-P: Alzheimer disease without psychosis; AD+P: Alzheimer disease with psychosis; AOO: age of onset; MMSE: Mini mental state exam</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" orientation="landscape" position="float">
<label>Table 2</label>
<caption>
<title>Risk score analysis: (A) Replication analysis of AD+P risk score; and (B) Schizophrenia risk score in two independent cohorts</title>
<p><bold>(A)</bold> AD+P risk score using all 60 SNPs with p &lt; 5 × 10<sup>−</sup>4 in the Discovery Cohort analysis that were genotyped in the independent Replication Cohort. Models included effects for weighted or unweighted risk score and ancestry eigenvectors. <bold>(B)</bold> Unweighted schizophrenia risk scores were calculated as standardized to number of SNPs available in each of the cohorts.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="1" rowspan="1" valign="top">b</th>
<th align="center" colspan="1" rowspan="1" valign="top">P</th>
<th align="center" colspan="1" rowspan="1" valign="top">OR</th>
<th align="center" colspan="1" rowspan="1" valign="top">95%CI-OR</th>
<th align="center" colspan="1" rowspan="1" valign="top">R<sup>2</sup>(%)<xref ref-type="table-fn" rid="TFN4">2</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1" valign="top">
<bold>A. AD+P Risk Score</bold>
</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Weighted Score</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.101</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.014<xref ref-type="table-fn" rid="TFN3">1</xref></td>
<td align="center" colspan="1" rowspan="1" valign="top">1.107</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.01–1.21</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Unweighted Score</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.107</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.010<xref ref-type="table-fn" rid="TFN3">1</xref></td>
<td align="center" colspan="1" rowspan="1" valign="top">1.113</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.02–1.22</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.34</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1" valign="top">
<bold>B. Schizophrenia Risk Score</bold>
</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Discovery Cohort</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.098</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.006</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.91</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.84–0.97</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.32</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Replication Cohort</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.091</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.030</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.91</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.83–1.00</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN2">
<p>AD+P: Alzheimer disease with psychosis. b: coefficient of the logistic regression (natural log of the odds ratio).</p>
</fn>
<fn id="TFN3">
<label>1</label>
<p>One-sided, prior hypothesis</p>
</fn>
<fn id="TFN4">
<label>2</label>
<p>Nagelkerke pseudo R<sup>2</sup>, this value is the R<sup>2</sup> attributed to the risk score</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" orientation="landscape" position="float">
<label>Table 3</label>
<caption>
<title>Meta-analysis of AD+P risk SNPs</title>
<p>The top three SNPs were located within <italic>RP11-541P9.3</italic> (an antisense transcript) 5′ to Cyclin G1 (<italic>CCNG1</italic>).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="2" rowspan="1" valign="top">Discovery</th>
<th align="center" colspan="2" rowspan="1" valign="top">Replication</th>
<th align="center" colspan="2" rowspan="1" valign="top">Meta-Analysis</th>
</tr>
<tr>
<th align="left" colspan="7" rowspan="1" valign="bottom">
<hr/></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="1" rowspan="1" valign="top">Risk Allele</th>
<th align="center" colspan="1" rowspan="1" valign="top">Z</th>
<th align="center" colspan="1" rowspan="1" valign="top">Risk Allele</th>
<th align="center" colspan="1" rowspan="1" valign="top">Z</th>
<th align="center" colspan="1" rowspan="1" valign="top">Z</th>
<th align="center" colspan="1" rowspan="1" valign="top">P</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>rs300215</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.921</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.933</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.530</td>
<td align="center" colspan="1" rowspan="1" valign="top">5.91e-6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>rs6859958</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.600</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.119</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.734</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.21e-6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>rs999581</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.763</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.857</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.725</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.36e-6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN5">
<p>AD+P: Alzheimer disease with psychosis</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" orientation="landscape" position="float">
<label>Table 4</label>
<caption>
<title>(A) SNPs that most consistently were associated with reduced AD+P risk. (B) SNPs that most consistently were associated with increased AD+P risk in the two cohorts</title>
<p>eQTL indicates genes whose brain expression was found to associate with the identified schizophrenia risk SNP (or its assay proxy) with a false discovery rate &lt; 0.05 in the CommonMind Consortium data set.<sup><xref ref-type="bibr" rid="R77">77</xref></sup> Sherlock indicates additional results of analyses of the CommonMind Consortium data set conducted using a Bayesian approach to prioritize consistency between the disease and eQTL associations in each of the schizophrenia GWAS loci.<sup><xref ref-type="bibr" rid="R87">87</xref></sup> This approach is motivated by recognition that the presence of an eQTL is not sufficient to indicate disease causality and that many SNPs within a locus are highly correlated, thus examination of the joint association of SNP and eQTL is more likely to identify genes contributing to disease risk. Genes identified by Sherlock with a corrected p &lt; 0.05 are shown.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="9" rowspan="1" valign="top">A. Top 20 SNPs Associated with Reduced AD+P Risk</th>
</tr>
<tr>
<th align="left" colspan="9" rowspan="1" valign="bottom">
<hr/></th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" valign="top">Chr</th>
<th align="center" colspan="1" rowspan="1" valign="top">Position (hg38)</th>
<th align="center" colspan="1" rowspan="1" valign="top">Variant</th>
<th align="center" colspan="1" rowspan="1" valign="top">Ref</th>
<th align="center" colspan="1" rowspan="1" valign="top">Alt</th>
<th align="center" colspan="1" rowspan="1" valign="top">Nearest Genecode Gene</th>
<th align="center" colspan="1" rowspan="1" valign="top">Sum of b</th>
<th align="center" colspan="1" rowspan="1" valign="top">eQTL</th>
<th align="center" colspan="1" rowspan="1" valign="top">Sherlock</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">243391917</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs10803138</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">SDCCAG8</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.365</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>SDCCAG8</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">109700365</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs4388249</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">MAN2A1</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.277</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>MAN2A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">57911057</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs75575209</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">VRK2</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.230</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">7</td>
<td align="center" colspan="1" rowspan="1" valign="top">131882504</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs7801375</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">15kb 5′ of AC009518.4</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.206</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">150059494</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs140505938</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">7.9kb 5′ of VPS45</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.200</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>CHTOP</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
<td align="center" colspan="1" rowspan="1" valign="top">88576397</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs7819570</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">RP11-586K2.1</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.198</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>ENSG00000253553</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>ENSG00000253553</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">11</td>
<td align="center" colspan="1" rowspan="1" valign="top">109507345</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs12421382</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">RP11-708B6.2</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.174</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">140764079</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs111896713</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12-mer</td>
<td align="center" colspan="1" rowspan="1" valign="middle">22kb 5′ of PCDHA1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">−0.171</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PCDHA7, PCDHA8, PCDHA13, PCDHA10, ZMAT2, PCDHA2, SRA1, NDUFA2, ANKHD1-EIF4EBP3, PCDHB3, PCDHAC2, WDR55</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">97368969</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs76869799</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">DPYD</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.162</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>ENSG00000259946</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">57760458</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs11682175</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">147kb 5′ of VRK2</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.161</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>FANCL</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">12</td>
<td align="center" colspan="1" rowspan="1" valign="top">110285440</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs4766428</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">ATP2A2</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.155</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>ANAPC7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">17</td>
<td align="center" colspan="1" rowspan="1" valign="top">18055088</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs8082590</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">C17orf39</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.146</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TOM1L2, DRG2, ATPAF2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TOM1L2, DRG2</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">X</td>
<td align="center" colspan="1" rowspan="1" valign="top">21362148</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs1378559</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">12kb 5′ of CNKSR2</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.143</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">154301187</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs11740474</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">GALNT10</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.140</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">175940150</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs1106568</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">GPM6A</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.131</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">36817092</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs75968099</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">9.7kb 3′ of TRANK1</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.128</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>MLH1, DCLK3, LRRFIP2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">145678654</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs56807175</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">TC</td>
<td align="center" colspan="1" rowspan="1" valign="top">75kb 5′ of AC079163.1</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.123</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">11</td>
<td align="center" colspan="1" rowspan="1" valign="top">133952674</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs75059851</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">IGSF9B</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.122</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">22</td>
<td align="center" colspan="1" rowspan="1" valign="middle">41944840</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1023500</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CENPM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">−0.120</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NAGA, CSDC2, WBP2NL, POLR3H</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NAGA</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">16</td>
<td align="center" colspan="1" rowspan="1" valign="top">9852462</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs9922678</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">GRIN2A</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.117</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">
<bold>B. Top 10 SNPs Associated with Increased AD+P Risk</bold>
</td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Chr</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Position (hg38)</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Variant</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Ref</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Alt</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Nearest Genecode Gene</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Sum of b</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>eQTL</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="bottom">
<hr/></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">18</td>
<td align="center" colspan="1" rowspan="1" valign="middle">55865958</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs72934570</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">16kb 3′ of RP11-214L13.1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.297</td>
<td align="center" colspan="1" rowspan="1" valign="middle">None</td>
<td align="center" colspan="1" rowspan="1" valign="middle">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">102225733</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs35518360</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">25kb 3′ of SLC39A8</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.284</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">20</td>
<td align="center" colspan="1" rowspan="1" valign="top">38824551</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs6065094</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">PPP1R16B</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.257</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">18</td>
<td align="center" colspan="1" rowspan="1" valign="top">55396445</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs78322266</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">TCF4</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.251</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">10</td>
<td align="center" colspan="1" rowspan="1" valign="top">102981826</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs55833108</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">CNNM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.192</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>BORCS7, AS3MT, INA</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">12</td>
<td align="center" colspan="1" rowspan="1" valign="top">2402665</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs2239063</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">CACNA1C</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.179</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">16</td>
<td align="center" colspan="1" rowspan="1" valign="top">68155437</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs8044995</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">NFATC3</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.128</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>PRMT7, ATP6V0D1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">136569563</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs7432375</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">STAG1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.116</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>PCCB</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>PCCB</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">12</td>
<td align="center" colspan="1" rowspan="1" valign="top">2235794</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs2007044</td>
<td align="center" colspan="1" rowspan="1" valign="top">A</td>
<td align="center" colspan="1" rowspan="1" valign="top">G</td>
<td align="center" colspan="1" rowspan="1" valign="top">CACNA1C</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.111</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">138515503</td>
<td align="center" colspan="1" rowspan="1" valign="top">rs3849046</td>
<td align="center" colspan="1" rowspan="1" valign="top">C</td>
<td align="center" colspan="1" rowspan="1" valign="top">T</td>
<td align="center" colspan="1" rowspan="1" valign="top">ETF1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.102</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
<td align="center" colspan="1" rowspan="1" valign="top">None</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN6">
<p>AD+P: Alzheimer disease with psychosis; Chr: Chromosome; hg38: Human Reference Genome Build 38; Ref: Reference Allele; Alt: Alternate Allele; Sum of b: sum of the SNP’s coefficients from the logistic regressions conducted in the two cohorts</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>